Comparing GLP regulatory standards

August 22, 2025

Introduction to GLP and Its Regulatory Context

Good Laboratory Practice (GLP) standards are essential for maintaining the reliability and integrity of non-clinical laboratory studies, especially in regulatory submissions for chemicals and pharmaceuticals. Understanding these standards and their comparisons with similar standards like GMP and GCP is crucial for professionals in pharmaceuticals and related fields.

What Defines Good Laboratory Practice (GLP)?

What are Good Laboratory Practice (GLP) standards?

Good Laboratory Practice (GLP) standards are a set of principles designed to promote quality and integrity in non-clinical laboratory studies. They ensure that studies are planned, executed, recorded, and reported systematically, maintaining high standards essential for regulatory compliance.

These guidelines focus on aspects such as training of personnel, proper organization, adequate facilities, equipment maintenance, and detailed standard operating procedures (SOPs). By adhering to GLP, laboratories can produce reliable data that is accepted internationally, facilitating regulatory approvals for new chemicals and pharmaceuticals.

Application of GLP in regulatory submissions

GLP is crucial when it comes to regulatory submissions, particularly in toxicological studies required for Investigational New Drug (IND) applications. Here are some points highlighting its significance:

  • Data Reliability : Ensures that test results are credible and reproducible.
  • Efficiency in Approvals : Streamlines the process of regulatory review, enhancing the speed of product approval.
  • Comprehensive Documentation : Requires thorough record-keeping that aids in future audits and inspections.

In essence, GLP lays the groundwork for safety assessments prior to new products entering the market, directly impacting public health and safety by regulating the quality of preclinical research.

Contrasting GLP with GMP Requirements

What is the difference between GLP and GMP?

GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) are both integral to maintaining quality within their respective domains, yet they serve distinct functions across the product development lifecycle.

  • Focus Area :

    • GLP emphasizes the reliability and integrity of non-clinical laboratory studies during research, concentrating on protocols, rigorous recordkeeping, and management approval structures.
    • GMP , on the other hand, ensures that products are consistently manufactured to specified quality standards, focusing heavily on consumer safety, contamination prevention, and efficacy during the manufacturing phase.
  • Key Components :

    • GLP guidelines involve organized management, trained personnel, and comprehensive study documentation that supports regulatory submissions.
    • GMP regulations enforce strict controls across the manufacturing process, often summarized as the 'Five Ps': People, Processes, Premises, Products, and Procedures.

Overall, GLPs govern the testing and data generation essential for regulatory compliance, while GMPs are crucial during the production and quality assurance stages of the final product.

Exploring the Distinctions Between GLP and GCP Standards

Overview of GLP and GCP

Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) are essential quality frameworks governing laboratory and clinical research, respectively. GLP regulations ensure the reliability and integrity of laboratory data, particularly in non-clinical experiments. In contrast, GCP guidelines, overseen by the International Conference on Harmonization (ICH), focus on safeguarding participants and maintaining the scientific quality of clinical trials.

GLP emphasizes thorough documentation, study director oversight, and adherence to standard operating procedures (SOPs) to foster trustworthy laboratory results. Meanwhile, GCP is structured around the ethical considerations of clinical trial methodology, including the need for protocols to be reviewed by an Institutional Review Board (IRB).

What is the difference between GLP and GCP regulations?

The distinctions between GLP and GCP regulations can be summarized as follows:

Aspect GLP GCP
Focus Laboratory data integrity and reliability Ethical treatment of participants and clinical data integrity
Oversight Study director and quality assurance roles Multiple investigators at clinical sites; IRB oversight
Data Requirements Requires archiving of raw data and detailed study protocols Involves additional elements like an investigator's brochure
Applications Applied to non-clinical studies (e.g., toxicity testing) Relevant to clinical trials involving human subjects

Both GLP and GCP play critical roles in the research landscape, ultimately ensuring the safety, efficacy, and ethical considerations of pharmaceuticals and other products.

Core Principles of Good Laboratory Practices (GLP)

What are the fundamental points of GLP?

The fundamental points of GLP (Good Laboratory Practices) encompass guidelines established by the FDA to ensure the reliability of non-clinical laboratory studies related to product safety and efficacy. These GLP standards are vital for maintaining integrity throughout the research process.

A significant aspect of GLP is its emphasis on rigorous documentation. Each laboratory activity, from sample handling to animal treatment, must be meticulously recorded. This extensive documentation is crucial for reliable data that can be audited or reviewed, reinforcing accountability in research protocols.

Another essential element is humane practices. GLP requires that animal welfare is prioritized, ensuring that studies adhere to ethical guidelines when involving test subjects. This care extends to providing clear protocols that must be documented, promoting humane treatment throughout the study.

Moreover, an ongoing stability program is mandated to monitor the longevity and reliability of products even after marketing. This program aids in the early detection of potential issues regarding product stability and integrity. GLP also requires the technical transfer of testing methods to be accompanied by written protocols. This ensures that quality and consistency are maintained when shifting methods between different labs.

Lastly, identifying and addressing Out of Expectation (OOE) events is critical within GLP. These deviations from expected results need prompt attention, as they can significantly impact compliance and the overall quality of the products being studied.

GLP and CLIA: Comparing Regulatory Roles in Biomarker Assays

How do GLP and other standards like CLIA differ in regulatory requirements for biomarker assays?

GLP (Good Laboratory Practice) and CLIA (Clinical Laboratory Improvement Amendments) differ significantly in their regulatory requirements for biomarker assays due to their distinct scopes and applications.

GLP is focused on maintaining the quality and integrity of nonclinical studies, specifically in the context of drug safety and efficacy evaluation. It ensures rigorous standards are met during preclinical research involving nonclinical specimens. This includes the generation of reliable data that supports safety assessments before any clinical trials can begin.

On the other hand, CLIA is concerned with the quality of laboratory testing performed on human samples. It emphasizes the need for accuracy and reliability in clinical tests crucial for patient care. Under CLIA guidelines, clinical laboratories are required to perform comprehensive validations of methods used for primary clinical endpoints. For exploratory endpoints, the validation requirements are less stringent, often allowing a fit-for-purpose approach based on guidelines from organizations such as CAP (College of American Pathologists) and CLSI (Clinical and Laboratory Standards Institute).

Regulatory scopes and requirements

The comparison table below illustrates the core differences between GLP and CLIA:

Aspect GLP CLIA
Focus Area Nonclinical research Clinical laboratory testing
Sample Types Nonclinical specimens (e.g., toxicology) Human samples
Validation Required Less stringent for exploratory work, rigorous for compliance Full method validation for primary endpoints, fit-for-purpose for exploratory endpoints
Oversight Body FDA, OECD CMS (Centers for Medicare & Medicaid Services)
Documentation Emphasis Comprehensive record keeping and adherence to SOPs Method validation and proficiency testing requirements

Thus, while both GLP and CLIA set high standards to ensure quality and reliability in laboratory standards, the specific requirements of GLP and CLIA reflect their tailored roles for nonclinical and clinical applications in the lifecycle of drug development.

Roles of Analytical Chemists Under GLP Standards

What are the roles of analytical chemists in GLP compliance within drug development?

Analytical chemists serve as the backbone of GLP compliance in drug development. Their primary responsibility involves developing and validating analytical methods that accurately characterize test articles. This includes determining their identity, strength, purity, and composition—factors that are critical for regulatory submissions.

They leverage established guidelines, such as ICH M10, to ensure drug concentration measurements in biological samples are precise. This adherence to rigorous standards is essential for maintaining the integrity of data generated during studies.

Moreover, good documentation practices (GDocP) are crucial. Analytical chemists meticulously follow Standard Operating Procedures (SOPs) to uphold the accuracy and reliability of laboratory results. This level of detail is necessary for preserving the evidence of compliance and integrity.

In addition, they ensure a chain of custody for test materials. This systematic approach guarantees that all materials and data are accounted for throughout the study process, enhancing the credibility of the results.

By supporting GLP principles, analytical chemists significantly contribute to the trustworthiness of safety data submitted to regulatory bodies like the FDA. Their role is vital for facilitating the approval of new drugs and ensuring public health safety.

The EPA's Role in GLP Compliance and Its Distinctive Features

EPA's GLP Regulations Under FIFRA and TSCA

The Environmental Protection Agency (EPA) has established Good Laboratory Practice Standards (GLPS) within the framework of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the Toxic Substances Control Act (TSCA) . These regulations ensure that test data submitted for pesticide product registration meet strict integrity and quality measures. By aligning closely with the FDA's GLP regulations , the EPA facilitates a smoother compliance experience for laboratory managers and toxicologists involved in pesticide studies.

Major Differences Between EPA and FDA GLP Compliance

While the EPA and FDA GLP regulations share many similarities (nineteen sections are nearly identical), notable differences exist:

Aspect EPA GLPS Regulations FDA GLP Regulations
Scope Broader, includes pesticides Focused on pharmaceuticals
Record Retention Period Minimum 10 years Minimum 5 years
Compliance Statement Requires a Statement of Compliance Not typically required
Effects of Noncompliance Significant legal implications Similar consequences outlined

These differences highlight operational factors that laboratories must consider when conducting studies under EPA GLPS compared to FDA GLPs. The EPA emphasizes longer record retention and specific compliance attestations, underscoring its rigorous approach to maintaining study integrity.

Conclusion: Navigating the Complexity of GLP Standards

Comparing GLP regulatory standards gives insight into the intricate landscape of regulatory compliance. With differences in focus, scope, and application, understanding GLP alongside GMP, GCP, and other standards such as CLIA provides critical knowledge for professionals involved in drug development and safety testing. Successful navigation of these standards ensures data credibility, participant safety, and consumer protection across various stages of product development, ultimately supporting the approval of safe and effective new products.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More